Unknown

Dataset Information

Is Intravenous and Oral Topotecan in Small-Cell Lung Cancer Truly Equal? A Case Report.


ABSTRACT:

Introduction

Treatment with topotecan is standard-of-care therapy for relapsed small-cell lung cancer (SCLC). Both oral and intravenous administrations of topotecan have been extensively researched and are found to be equally effective with less adverse events in the oral group.

Case presentation

We report a case of a patient with SCLC, who had previously received oral topotecan, with radiological stable disease with no changes in tumor or metastasis diameter size after two administrations. Subsequently, this patient received intravenous topotecan instead of oral due to supply difficulties. After one administration of intravenous topotecan, we saw significant disease regression.

Conclusion

This is to our knowledge the first reported case of better response of intraven

SUBMITTER: Deraedt D 

PROVIDER: S-EPMC11521484 | biostudies-literature | 2024 Jan-Dec

REPOSITORIES: biostudies-literature